Web Analytics

3 Latest Announced Rounds

$2,245.57M Raised in 89 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Boundless Bio

start up
United States - La Jolla, California
  • 17/05/2023
  • Series C
  • $100,000,000

Boundless Bio is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence.

When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive.

Our Culture:

At Boundless, you’ll experience what it means to be out in front of the wave.
Our unprecedented science takes us to new shores, and our team navigates the best breaks. We’re leaders in our field, and we’re dedicated to the cause of understanding and treating intractable cancers.

Every employee at Boundless makes an unbridled impact on our capabilities and our culture. We’ll help you expand your abilities and defy your bounds by providing meaningful work and unbounded opportunities. Career development is essential at Boundless.

We’re all in on this fight against cancer– collaboration is requisite to our success. We have a team of people who ask, offer, and accept help without regard for ego. We know that receiving support is energizing, and giving help is fulfilling. We are inspired by the patients who are reliant upon our success.

At Boundless, we’re all in. We are unbound by convention, bound to save lives.


Career Inquiries
careers@boundlessbio.com

General Information Inquiries
info@boundlessbio.com


Related People

Zachary HornbyFounder

Zachary Hornby United States - San Diego, California

CEO, President, and Director at Boundless Bio, Inc.
Experienced Biotechnology Executive who has built a company from business plan to IPO, to integrated public company with robust clinical pipeline and international development capabilities, to successful exit ($1.7B acquisition by Roche): Eighteen years of industry leadership roles and operational experience in private and public companies in Executive Management, Operations, Finance, Business and Corporate Development, New Product Planning, Marketing, Medical Affairs, Diagnostics and Regulatory Affairs. Have overseen multiple scientific functions (Medical Affairs, Translational Research, Diagnostics, Computational Biology, Quality) and multiple administrative functions (Finance, Corporate Development, Commercial, Operations, HR, Team Leadership, Program Management, IT and Facilities) for a leading oncology precision medicine company. Operational roles build upon solid biology background underpinned by bachelor’s and master’s degrees (Stanford, biology [neuroscience]), supplemented by clinical research and bench science. Industry experience rounded out by strategic business perspective developed through biotech consulting (L.E.K.) and an MBA (Harvard).